BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36430665)

  • 1. sFlt-1 in Chronic Kidney Disease: Friend or Foe?
    Matsui M; Onoue K; Saito Y
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the PlGF/Flt-1 signaling pathway in the cardiorenal connection.
    Saito Y
    J Mol Cell Cardiol; 2021 Feb; 151():106-112. PubMed ID: 33045252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease.
    Matsui M; Takeda Y; Uemura S; Matsumoto T; Seno A; Onoue K; Tsushima H; Morimoto K; Soeda T; Okayama S; Somekawa S; Samejima K; Kawata H; Kawakami R; Nakatani K; Iwano M; Saito Y
    Kidney Int; 2014 Feb; 85(2):393-403. PubMed ID: 24048373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.
    Gu Y; Lewis DF; Wang Y
    J Clin Endocrinol Metab; 2008 Jan; 93(1):260-6. PubMed ID: 17956952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
    Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
    Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placenta growth factor and sFlt-1 as biomarkers in ischemic heart disease and heart failure: a review.
    Draker N; Torry DS; Torry RJ
    Biomark Med; 2019 Jun; 13(9):785-799. PubMed ID: 31157982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta.
    Li H; Gu B; Zhang Y; Lewis DF; Wang Y
    Placenta; 2005; 26(2-3):210-7. PubMed ID: 15708122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of angiogenic factors in women with chronic kidney disease and suspected superimposed preeclampsia.
    Molina-Pérez CJ; Nolasco-Leaños AG; Carrillo-Juárez RI; Leaños-Miranda A
    J Nephrol; 2022 Jul; 35(6):1699-1708. PubMed ID: 35353367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
    Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
    Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia.
    Lecarpentier E; Zsengellér ZK; Salahuddin S; Covarrubias AE; Lo A; Haddad B; Thadhani RI; Karumanchi SA
    Hypertension; 2020 Sep; 76(3):875-883. PubMed ID: 32654553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia.
    Tang P; Xu J; Xie BJ; Wang QM
    Hypertens Pregnancy; 2017 Feb; 36(1):48-52. PubMed ID: 27834501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imbalance of growth factors mRNA expression associated with oxidative stress in the early pregnancy loss.
    Galaziou A; Filidou E; Spathakis M; Arvanitidis K; Arzou BC; Galazios G; Koutlaki N; Nikolettos N; Kolios G
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6150-6156. PubMed ID: 33820497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
    Brownfoot FC; Hannan NJ; Cannon P; Nguyen V; Hastie R; Parry LJ; Senadheera S; Tuohey L; Tong S; Kaitu'u-Lino TJ
    EBioMedicine; 2019 Mar; 41():636-648. PubMed ID: 30824385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
    Ren Z; Cui N; Zhu M; Khalil RA
    Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women.
    Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S
    J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental growth factor blunts uterine artery responses to angiotensin II.
    Espinoza J; Betancourt A; Belfort MA; Shamshirsaz AA; Fox KA; Yallampalli C
    BJOG; 2019 Jul; 126(8):1058-1064. PubMed ID: 30771259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies.
    Hoeller A; Ehrlich L; Golic M; Herse F; Perschel FH; Siwetz M; Henrich W; Dechend R; Huppertz B; Verlohren S
    Hypertens Pregnancy; 2017 May; 36(2):151-160. PubMed ID: 28609172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum placental growth factor (PlGF) as biomarkers for ectopic pregnancy and missed abortion.
    Daponte A; Pournaras S; Polyzos NP; Tsezou A; Skentou H; Anastasiadou F; Lialios G; Messinis IE
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1444-51. PubMed ID: 21715541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.